This week, the focus will once again be on the BioNTech share. In the European Union, BioNTech’s COVID-19 vaccine BNT162 is expected to be approved, which the Mainz-based company and US pharmaceutical company Pfizer brought to market in record time. The current news about mutations of the SARS-CoV-2 virus make approval anything but unlikely, especially since the vaccine should also be effective against mutated versions of the pathogen.
In terms of charts, the BioNTech share is undergoing a potential stabilization after its recent downward movement from the all-time high of $ 131 on Thursday, reaching $ 101.62. The 50-day line at currently $ 101.91, which offered the stabilization zone for BioNTech’s share price for three trading days in a row, is helpful here. On the other hand, the question of how much of the good news about BioNTech is already included in the course remains extremely interesting.